|
| Population with IAT stage† HCC treated with sorafenib | Total | Sorafenib after TACE only | Sorafenib after TARE only | Sorafenib only |
| 4,658 (100%) | 1,079 (23.2%) | 113 (2.4%) | 3,466 (74.4%) |
|
| Gender male (%) | 4,063 (87.2%) | 950 (88.0%) | 97 (85.8%) | 3,016 (87.0%) |
| Age (years) at identification of IAT stage† HCC: mean (SD) | 67.2 (9.9) | 67.0 (9.3) | 64.8 (11.0) | 67.4 (10.0) |
| Duration of follow up: mean (SD) (month) | 7.9 (7.3) | 8.9 (7.5) | 7.6 (6.2) | 7.6 (7.2) |
| HCC aetiology (one answer only) | | | | |
| Alcohol without viral hepatitis‡ | 1,949 (41.8%) | 507 (47.0%) | 41 (36.3%) | 1,401 (40.4%) |
| Alcohol- and viral hepatitis-related liver disease‡ | 404 (8.7%) | 112 (10.4%) | 18 (15.9%) | 274 (7.9%) |
| Viral hepatitis-related liver disease without alcohol‡ | 682 (14.6%) | 189 (17.5%) | 22 (19.5%) | 471 (13.6%) |
| Metabolic risk factors | 833 (17.9%) | 162 (15.0%) | 11 (9.7%) | 660 (19.0%) |
| Other liver diseases | 268 (5.8%)) | 53 (4.9%) | 8 (7.1%) | 207 (6.0%) |
| No identified liver disease or diabetes mellitus | 522 (11.2%) | 56 (5.2%) | 13 (11.5%) | 453 (13.1%) |
| History of HCC curative treatment or type of disease progression | | | | |
| Previous curative treatment | 1,061 (22.8%) | 325 (30.1%) | 26 (23.0%) | 710 (20.5%) |
| No curative treatment (de novo IAT stage† at HCC diagnosis) | 2,959 (63.5%) | 686 (63.6%) | 86 (76.1%) | 2,187 (63.1%) |
| Undetermined (lack of retrospective data) | 638 (13.7%) | 68 (6.3%) | 1 (0.9%) | 569 (16.4%) |
| Sorafenib treatment modalities | | | | |
| Number of deliveries |
| Mean (SD) number of sorafenib deliveries during the study period | 3.7 (3.8) | 3.9 (3.9) | 3.4 (3.0) | 3.7 (3.9) |
| Only one delivery of sorafenib | 1,495 (32.1%) | 309 (28.6%) | 39 (34.5%) | 1,147 (33.1%) |
| 2 sorafenib deliveries | 914 (19.6%) | 201 (18.6%) | 22 (19.5%) | 691 (19.9%) |
| ≥3 sorafenib deliveries | 2,249 (48.3%) | 569 (52.7%) | 52 (46.0%) | 1,628 (47.0%) |
| Analysis in patient subgroup who received ≥2 sorafenib deliveries | | | | |
| Number of patients (%) | 3,163 (67.9%) | 770 (71.4%) | 74 (65.5%) | 2,319 (66.9%) |
| Sorafenib dose | | | | |
| Daily dose (mg): mean (SD) | 762 (612) | 717 (321) | 804 (553) | 775 (683) |
| ≥1 dose adaptation (patients) | 1,128 (35.7%) | 293 (38.0%) | 23 (31.1%) | 812 (35.0%) |
| In patients alive at treatment discontinuation | 1,067 (33.7%) | 286 (38.1%) | 26 (35.1%) | 755 (32.6%) |
| No deaths observed during the study period | 407 (12.9%) | 115 (14.9%) | 12 (16.2%) | 280 (12.1%) |
| Delayed death after the treatment discontinuation | 660 (20.9%) | 171 (22.2%) | 14 (18.9) | 475 (20.5%) |
| Median survival: month (95% CI) | 7.3 (7.0 -7.7) | 10.4 (9.7-11.2) | 8.2 (6.0 -8.8) | 6.5 (6.2 -6.9) |
|
